

# Lawrence J Stern

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2332598/publications.pdf>

Version: 2024-02-01

36  
papers

1,456  
citations

257450

24  
h-index

345221

36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2110  
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation. <i>Current Opinion in Immunology</i> , 2014, 26, 115-122.	5.5	119
2	HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 90-98.	8.2	99
3	Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 395-406.	8.2	87
4	HLA-DR: Molecular Insights and Vaccine Design. <i>Current Pharmaceutical Design</i> , 2009, 15, 3249-3261.	1.9	78
5	Class II MHC antigen processing in immune tolerance and inflammation. <i>Immunogenetics</i> , 2019, 71, 171-187.	2.4	77
6	Conformational lability in the class II MHC 3 <sup>10</sup> helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19329-19334.	7.1	70
7	The kinetic basis of peptide exchange catalysis by HLA-DM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 12450-12455.	7.1	67
8	Model for the Peptide-Free Conformation of Class II MHC Proteins. <i>PLoS ONE</i> , 2008, 3, e2403.	2.5	60
9	Conformational variation in structures of classical and nonclassical MHCII proteins and functional implications. <i>Immunological Reviews</i> , 2012, 250, 144-157.	6.0	59
10	Enhanced Catalytic Action of HLA-DM on the Exchange of Peptides Lacking Backbone Hydrogen Bonds between their N-Terminal Region and the MHC Class II $\alpha$ -Chain. <i>Journal of Immunology</i> , 2004, 172, 1109-1117.	0.8	57
11	Human CD4+ T Cell Epitopes from Vaccinia Virus Induced by Vaccination or Infection. <i>PLoS Pathogens</i> , 2007, 3, e144.	4.7	51
12	HLA-DM Constrains Epitope Selection in the Human CD4 T Cell Response to Vaccinia Virus by Favoring the Presentation of Peptides with Longer HLA-DM-Mediated Half-Lives. <i>Journal of Immunology</i> , 2012, 189, 3983-3994.	0.8	51
13	Susceptibility to HLA-DM Protein Is Determined by a Dynamic Conformation of Major Histocompatibility Complex Class II Molecule Bound with Peptide. <i>Journal of Biological Chemistry</i> , 2014, 289, 23449-23464.	3.4	49
14	<i>Shigella</i> depends on SepA to destabilize the intestinal epithelial integrity via cofilin activation. <i>Gut Microbes</i> , 2017, 8, 544-560.	9.8	46
15	Structure Induction of the T-Cell Receptor $\alpha$ -Chain upon Lipid Binding Investigated by NMR Spectroscopy. <i>ChemBioChem</i> , 2007, 8, 820-827.	2.6	39
16	In vivo clonal expansion and phenotypes of hypocretin-specific CD4+ T cells in narcolepsy patients and controls. <i>Nature Communications</i> , 2019, 10, 5247.	12.8	39
17	GM-CSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. <i>Immunology Letters</i> , 2008, 116, 41-54.	2.5	38
18	Antigen-specific T cell phenotyping microarrays using grating coupled surface plasmon resonance imaging and surface plasmon coupled emission. <i>Biosensors and Bioelectronics</i> , 2012, 31, 264-269.	10.1	35

#	ARTICLE	IF	CITATIONS
19	Quantitative Profiling of the Lymph Node Clearance Capacity. <i>Scientific Reports</i> , 2018, 8, 11253.	3.3	35
20	The melting pot of the MHC II peptidome. <i>Current Opinion in Immunology</i> , 2016, 40, 70-77.	5.5	33
21	HLA-DO Modulates the Diversity of the MHC-II Self-peptidome. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 490-503.	3.8	33
22	A temporal thymic selection switch and ligand binding kinetics constrain neonatal Foxp3+ Treg cell development. <i>Nature Immunology</i> , 2019, 20, 1046-1058.	14.5	31
23	Exploration of the P6/P7 Region of the Peptide-binding Site of the Human Class II Major Histocompatibility Complex Protein HLA-DR1. <i>Journal of Biological Chemistry</i> , 2003, 278, 44904-44912.	3.4	30
24	Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 103-121.	6.4	30
25	Conformational dynamics linked to domain closure and substrate binding explain the ERAP1 allosteric regulation mechanism. <i>Nature Communications</i> , 2021, 12, 5302.	12.8	22
26	Evaluating the Role of HLA-DM in MHC Class II Peptide Association Reactions. <i>Journal of Immunology</i> , 2015, 195, 706-716.	0.8	21
27	CDR3 drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection. <i>PLoS Pathogens</i> , 2019, 15, e1008122.	4.7	21
28	Molecular pathways for antigenic peptide generation by ER aminopeptidase 1. <i>Molecular Immunology</i> , 2019, 113, 50-57.	2.2	17
29	The cytosolic domain of T-cell receptor $\zeta$ associates with membranes in a dynamic equilibrium and deeply penetrates the bilayer. <i>Journal of Biological Chemistry</i> , 2017, 292, 17746-17759.	3.4	14
30	Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1429-1434.	2.8	11
31	A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC50 determination. <i>Journal of Immunological Methods</i> , 2014, 406, 21-33.	1.4	10
32	A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B. <i>PLoS ONE</i> , 2015, 10, e0142871.	2.5	9
33	Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. <i>Nature Communications</i> , 2019, 10, 3134.	12.8	9
34	The N-terminal region of photocleavable peptides that bind HLA-DR1 determines the kinetics of fragment release. <i>PLoS ONE</i> , 2018, 13, e0199704.	2.5	5
35	Recognition of <i>Listeria</i> Infection by Germline Elements of the V $\beta$ 1.1 V $\beta$ 6.3 TCR. <i>ImmunoHorizons</i> , 2019, 3, 341-351.	1.8	2
36	Phenylsulfamoyl Benzoic Acid Inhibitor of ERAP2 with a Novel Mode of Inhibition. <i>ACS Chemical Biology</i> , 2022, 17, 1756-1768.	3.4	2